Jim Doherty, President and Chief Development Officer at Acumen Pharmaceuticals, shares his extensive experience in developing therapies for CNS diseases. He discusses the historical challenges of Alzheimer’s treatment, the controversies over new amyloid-targeting drugs, and the pivotal role of biomarkers in personalized medicine. Highlighting Acumen's promising candidate, Sobernatug, he reveals its innovative approach to targeting soluble A-beta oligomers, while emphasizing the importance of collaboration and evolving strategies in CNS drug development.
